An interventional study of SCOPE-Chinese Women in Cancer, Breast and Obesity, Abdominal, sponsored by University of California, San Francisco. Completed at 2 sites in 2 countries. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by University of California, San Francisco · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Breast Neoplasms by University of California, San Francisco — 11 open to participants now, 16 under way, 1 of them phase 3. Breast Neoplasms · University of California, San Francisco.
Among the 62 studies in Breast Neoplasms by University of California, San Francisco, this one is the 13th largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2020, is one of 23 with no phase, and was the 45th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →11 of the 62 studies in Breast Neoplasms by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 40–89 · Women only · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 19 · Phase 3 1 · Phase 4 2
First in 2001; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 38 across the 49 interventional studies, 79 across the 12 observational. Of the 46 that completed or were terminated, 18 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
7 of the studies in Breast Neoplasms by University of California, San Francisco that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05020574University of California, San FranciscoMicrobiome and Association With Implant Infections | 2026-12-31 |
| NCT07512271University of California, San FranciscoGenerative AI Patient Education Module for Breast Oncology | 2027-01-31 |
| NCT07121972University of California, San FranciscoMirai-MRI: Validation of AI Models for Breast Cancer Risk | 2027-01-31 |
| NCT06648278University of California, San FranciscoPatient Care Outreach, Navigation, Technology and Support 2.0 | 2027-02-28 |
| NCT05056077University of California, San FranciscoImproving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit) | 2027-04-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 62 studies in Breast Neoplasms by University of California, San Francisco, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project examines the feasibility of a smartphone-based intervention to reduce obesity and breast cancer risk among Chinese women in China. The proposed intervention is to use the mobile application and an activity tracker device to promote a healthier lifestyle and physical activity. The intervention will be tailored to the participants' behaviors, personal needs, and preferences. The aim is to reduce abdominal obesity and improve healthy lifestyle behaviors in premenopausal women with children in order to reduce the growing cancer burden in China.
Cancer presents a major disease burden across the globe. The incidence and mortality of gynecologic cancers have increased significantly in China over the last two decades with breast and endometrial cancer as leading causes of death in women in China. Obesity, especially abdominal obesity, and unhealthy lifestyles are major risk factors for breast and endometrial cancer. A high risk group for obesity is mothers with dependent children as they have high levels of stress and family responsibilities that prevent regular engagement in a healthy lifestyle and early screening activities. Because reducing postmenopausal abdominal obesity is very difficult and because of the significant increased risk for gynecologic cancers in obese postmenopausal women, interventions that aim to reduce abdominal obesity and improve healthy lifestyle behaviors in premenopausal women with children are critical to reducing the growing cancer burden in China. A smartphone-based intervention provides a promising platform for obesity and cancer prevention. In this proposed study, the research team will modify the Healthy Mothers Healthy Children: Technology-Based Intervention to Prevent Obesity, which was developed by the principal investigator. The proposed intervention (titled "The Smartphone-Based Cancer and Obesity Prevention Education Program for Chinese Women: SCOPE-Chinese Women") is a smartphone-based, data-driven, and individually tailored intervention. It includes 12 weekly educational modules and six bi-weekly tailored messages delivered via WeChat, a popular communication app in China. The intervention will also be tailored to the participants' behaviors, personal needs, and preferences. The overall goal of this proposed study is to assess the feasibility and estimate the preliminary efficacy of the SCOPE-Chinese Women intervention using a randomized control study design (RCT). The following aims will be addressed.
Aim 1: To assess the feasibility of the smartphone-based lifestyle intervention (i.e., SCOPE-Chinese Women).
Aim 2: To estimate the preliminary efficacy of the SCOPE-Chinese Women intervention on the primary outcome (waist circumference) and secondary outcomes (body mass index, self-efficacy, food intake, physical activity, and metabolic risk) between the intervention and control groups at baseline, 3 months, and 6 months.
Aim 3: To understand participants' acceptance, barriers to adherence, and recommendations for intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must:
Exclusion Criteria:
Women are excluded from the study if they:
Participants in the control group will receive a Fitbit Alta-Heart Rate (HR) and 12 weekly non-tailored educational modules via WeChat on general health topics that are important to 20-45 year-old women in China. Topics include intimate partner violence, anxiety, depression, sexually transmitted infections, HIV, unintended pregnancy, hepatitis B, and general cancer prevention.
SCOPE-Chinese Women intervention content and methods: SCOPE-Chinese Women is a smartphone- based intervention. Component 1. All study participants will receive a Fitbit Alta-HR tracking device to wear daily. Each participant will receive in-person, training on how to access the app and their tracking data. If a participant has not used the fitness device and app for more than one week, a WeChat reminder message will be sent to the participant. Component 2. Participants will receive 12 weekly culturally appropriate and evidence-based SCOPE-Chinese Women educational modules along with tailored tips and messages via WeChat. Each module will include three educational sessions that last less than 45 minutes total. Component 3. Six bi-weekly messages will be sent to participants via WeChat to encourage positive behavioral changes. Each participant's message content will be based on the participant's tracker information, personal goals, and preferences.
Other: SCOPE-Chinese Women
SCOPE-Chinese Women is a smart-phone based intervention that includes a Fitbit tracking device to monitor daily activity, 12-weeks of educational modules delivered by WeChat, and Bi-weekly messages that encourage positive behavioral change. The data will be examined by the research team to assess efficacy of the intervention.
Mean Change in Waist Circumference Over Time
The National Institutes of Health (NIH) waist circumference measurement protocol will be used to measure change in waist circumference for each participant over time.
Time frame: Baseline, 3 months, and 6 months
Mean Change in Body Mass Index (BMI) Over Time
Weight and height will be used to compute the BMI with the formula=weight (kilograms(kg)) / height in (meters squared (m2). Changes in BMI will be collected for each participant over time.
Time frame: Baseline, 3 months, and 6 months
Mean Change in Scores on the Self-Rated Abilities for Health Practices Scale Over Time
The Self Rated Abilities for Health Practices Scale (SRAHP) is a 28-item survey, with each item scored on a 5-point scale, with item scores ranging from 0=Not at all to 4=Completely. The survey is designed to measure self-perceived ability to implement health-promoting behaviors across four subscales: Exercise, Nutrition, Responsible Health Practice, and Psychological Well Being, and overall. The total score ranges from 0 - 112, with higher scores indicating greater abilities for health practices. Changes in scores will be collected for each participant over time.
Time frame: Baseline, 3 months, and 6 months
Mean Changes in China Food Frequency Questionnaire (FFQ) over time.
Food intake using the China food frequency questionnaire (FFQ), which includes a list of 118 food items will be used to measure aggregate changes in food intake over time.
Time frame: Baseline, 3 months, and 6 months
Mean Changes in Overall Physical Activity
Change in overall Physical activity over time will be measured using the Fitbit Alta-HR device for 10 hours while participants are awake.
Time frame: Baseline, 3 months, and 6 months
Mean Change in Blood Pressure Over Time
Changes in blood pressure will be measured using the YuWell YE690A monitor for each participant over time.
Time frame: Baseline, 3 months, and 6 months
Mean Change in Hemoglobin A1C (HbA1C) Over Time
A blood sample will be collected to measure change in HbA1C over time for each participant, using an established cut off value at 6.4%.
Time frame: Baseline and 6 months
Mean Change in Serum Lipid Levels Over Time
A blood sample will be collected to measure change in total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides (all measured in milligrams per deciliter (mg/dL)) over time for each participant
Time frame: Baseline and 6 months
Mean Change in Cortisol over time
A blood sample will be collected to measure change in total cortisol levels over time for each participant.
Time frame: Baseline and 6 months
Relative telomere length (RTL)
A blood sample will be collected to measure relative telomere length (RTL), assessed using the real-time quantitative polymerase chain reaction (qPCR) technique, adhering to the protocol specified by Cawthon.
Time frame: baseline and 6 months follow-up.
Percentage of Eligible participants Who Agree To Be Screened
The number of overall eligible participants and the number of eligible participants who agree to be screened will be used to compute the percentage used for enrollment.
Time frame: At Baseline
Number of Uses of The Tracking App Over Time
The number of uses of the tracking app and frequency of accessing the 12 modules, to measure change in usability over time
Time frame: Baseline to 6 months
Percentage of Participants who completed assessments
The percentage of completed assessments by participants at each visit will be used to measure adherence over time
Time frame: Up to 6 months
Plan to share: No
Ran from Jul 2020 to primary completion in Dec 2022, 29 months.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 29 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2021 → Dec 2022 and completion Dec 2021 → Dec 2022.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →